Clinical trials: Anti-inflammatory Agent
Rheumatoid Arthritis
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment
This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of…
- Trial name
- CONIFER (NCT03112213)
- Testing
- Tocilizumab, NSAIDs
- Where
- 27 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
Primary Objective: To evaluate the effect of irbesartan/atorvastatin fixed-dose combination comparing to each irbesartan and atorvastatin on flow mediated dilation change in type 2 diabetic patients diagnosed with hyperlipidemia…
- Trial name
- NCT02842359
- Testing
- Irbesartan/atorvastatin fixed dose combination, Irbesartan SR47436, Atorvastatin
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Sanofi
Dyspepsia, Chronic Gastritis
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
To study the anti free radical \& inflammatory effect and safety of Rebamipide in patients suffering of dyspepsia due to chronic gastritis.
- Trial name
- NCT00996788
- Testing
- Rebamipide
- Where
- Indonesia
- Volunteers
- 55 people
- Sponsor
- PT Otsuka Indonesia
Colitis, Ulcerative, Crohn Disease
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and…
- Trial name
- EVOLVE-IBERIA (NCT03710486)
- Where
- 26 sites in Portugal, Spain
- Volunteers
- 409 people
- Sponsor
- Takeda
Lung Injury, Acute
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress…
- Trial name
- NCT00996840
- Testing
- SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
- Trial name
- PRADA (NCT02896985)
- Where
- 24 sites in Canada
- Volunteers
- 98 people
- Sponsor
- AbbVie
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal…
- Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
- Trial name
- RESOLUTION (NCT07085104)
- Testing
- ALLO-329, Cyclophosphamide, Fludarabine
- Where
- 17 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Allogene Therapeutics
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
This is a 2-part randomized, double-blind, placebo-controlled study followed by an open-label extension (OLE) of APT-1011 in adults with EoE.
- Trial name
- FLUTE-2 (NCT04281108)
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 56 sites in United States, Australia and 1 more
- Volunteers
- 143 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Cataract Extraction, Cataract
Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction
Cataract is an ophthalmic disease that usually affects the elderly population. Cataract surgery with phaco-emulsification is now the most frequently performed intraocular surgical procedure in the developed world.
- Trial name
- NCT02973880
- Testing
- NETILDEX™ ophthalmic gel, NETILDEX™ eye drops solution
- Where
- 7 sites in Germany, Italy and 1 more
- Volunteers
- 180 people
- Sponsor
- SIFI SpA
Overweight, Healthy
Maximizing the Anti-inflammatory Effects of Strawberry Bioavailability
Primary objective is to determine if the efficacy of strawberries delivering polyphenols to prevent metabolic inflammation will be influenced by timing of consumption relative to meal intake.
- Trial name
- NCT01856153
- Testing
- Before meal, With Meal, After meal
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Coronary Heart Disease
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT00291902
- Testing
- SB-681323
- Where
- 7 sites in Denmark, Poland
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
This two-stage, multicenter clinical trial is designed to evaluate the feasibility, safety, and preliminary efficacy of splenic ultrasound stimulation to activate immune-neuromodulation (SUSTAIN) in patients with rheumatoid…
- Trial name
- SUSTAIN (NCT07293871)
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Surf Therapeutics
Osteoarthritis, Knee
Follow on Extension of XT-150-1-0201
XT-150 safety and efficacy in severe osteoarthritic pain.
- Trial name
- NCT03769662
- Testing
- XT-150
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Xalud Therapeutics, Inc.
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Acute Kidney Injury Due to Sepsis
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting…
- Trial name
- CLEAR-AKI (NCT05996835)
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy will be investigated.
- Trial name
- NCT01568385
- Testing
- TAK-438
- Where
- 18 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Takeda
Postoperative Bariatric Surgery
Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Phase IV, open-label, multicenter, non-randomized, with 2 non-comparative investigational arms study, carried out in morbid obesity patients who had undergone gastric bypass surgery for body weight reduction
- Trial name
- NCT00608712
- Testing
- Esomeprazole
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.
- Trial name
- FLUTEEN (NCT05083312)
- Testing
- APT-1011
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Ellodi Pharmaceuticals, LP